uniQure Stock Plunges 7%, Wiping Out $129 Million, Even After FDA Grants Priority Review

The Huntington's gene therapy now has a May 1, 2027 FDA target date, but shares gave up an early gain at Monday's close.

Share
uniQure Stock Plunges 7%, Wiping Out $129 Million, Even After FDA Grants Priority Review

uniQure shares fell 7.49% to $22.97 at Monday's close, erasing $129 million in market value, on the day the gene therapy developer said the FDA granted priority review to its Huntington's disease treatment. The agency set a May 1, 2027 target action date, according to an 8-K the company filed.

A rally that reversed

The stock climbed as high as $26.60 during the session, up 7.1% from the previous close, before turning lower as the day went on. It was uniQure's biggest one-day drop since Sept. 29, when the shares fell 37.3%.

Next steps include a possible FDA advisory panel, still tentative, and patient screening for a roughly 200-person confirmatory trial, which uniQure expects to start before the end of 2026.

A one-time therapy for Huntington's

uniQure develops gene therapies, one-time treatments meant to attack rare and serious diseases at their genetic source. Its candidates target Huntington's disease, refractory mesial temporal lobe epilepsy, Fabry disease and a form of ALS caused by SOD1 mutations. It also has HEMGENIX, a hemophilia B therapy for which CSL Behring holds exclusive global rights.

Huntington's affects roughly 75,000 people in the US, EU and UK combined, according to a summary of the company's release.

The therapy, AMT-130, is headed toward approval under the FDA's accelerated pathway. In its second-quarter release, the company said FDA meeting minutes confirmed that filing for accelerated approval on existing clinical data is reasonable. The agency also wants the confirmatory study well underway, and potentially fully enrolled, when approval would come.

Cash into 2030, shares up 4% this year

The same release described a $259 million follow-on offering that extended the company's cash runway into 2030. In June, uniQure closed an upsized offering of 5,686,813 shares at $45.50 each.

As of Friday's close, the stock was up about 4% for the year, trailing the S&P 500's gain of about 11%. It sat 63% below its highest close of the past year, with a market value of $1.6 billion.

uniQure is scheduled to report third-quarter results on Wednesday, Nov. 4.

Sources

More on uniQure

All uniQure (QURE) coverage →